solute carrier family 35 member F6Genealiases: ANT2BP · C2orf18 · TANGO9
Q-omics provides the consensus-scored SLC35F6 profile across patient tissues and cancer cell-line models. SLC35F6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SLC35F6 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, SLC35F6 RNA expression shows 19,001 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where SLC35F6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC35F6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC35F6 survival associations across molecular data types. SLC35F6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC35F6 RNA expression–survival associations across cancer types. High SLC35F6 expression shows unfavorable associations in UVM, BLCA, LIHC, LGG, ACC and LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SLC35F6 RNA expression.
This table summarizes SLC35F6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC35F6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC35F6 shows higher tumor expression in KIRC, HNSC, COAD, LIHC, KIRP and BLCA. The KIRC box plot shows higher SLC35F6 RNA expression in tumor versus normal tissue (log2 FC = +1.038, t-test p < 0.001).
This table shows molecular features associated with SLC35F6 in patient tissues and cancer cell lines. In patient samples, SLC35F6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC35F6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and UPPER_AERODIGESTIVE_TRACT.
